1 / 11

Global Eylea Market Analysis (2024-2030)

Apelo Consulting has released a report on u201cGlobal Eylea Market (By Disorder, Product, End User, Region), Company profiles and Market Dynamics u2013 Forecast to 2030u201d

ApeloConsulting
Télécharger la présentation

Global Eylea Market Analysis (2024-2030)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL EYLEA MARKET ANALYSIS 2024-2030 Comprehensive Market Overview | Growth Drivers | Segmentation | Regional Insights | Future Outlook Prepared by Apelo Consulting October 2025 Global Eylea Market Analysis Apelo Consulting 1

  2. EXECUTIVE SUMMARY The global Eylea market was valued at USD 9,714 Million in 2024, projected to reach USD 14,545 Million by 2030. Robust growth driven by rising retinal diseases, aging demographics, and innovative treatment formats. Widespread adoption across all regions and key end user segments. Backed by strong clinical evidence and robust safety profile. Key Growth Rate ~7% CAGR 2024-2030 Forecast Period Global Eylea Market Analysis | Executive Summary Apelo Consulting 2

  3. What is Eylea? (Aflibercept) Eylea (aflibercept) is a potent anti-VEGF therapy that inhibits abnormal blood vessel growth in the retina Primary Medical Applications: Wet Age-related Macular Degeneration (AMD) Administered ophthalmologists via intravitreal injection by Leading cause of vision loss in adults over 50 Diabetic Macular Edema (DME) Redefined standards for retinal disease management over the past decade Complication of diabetes affecting vision Backed by robust clinical evidence with a consistent safety profile Diabetic Retinopathy (DR) Progressive damage to retina due to diabetes Retinal Vein Occlusion (RVO) Key Benefit Blockage of veins carrying blood from retina Improves vision and reduces risk of blindness in patients with retinal diseases Myopic Choroidal Neovascularization (mCNV) Complication of severe near-sightedness Global Eylea Market Analysis | What is Eylea? Apelo Consulting 3

  4. Market Growth Drivers Aging Population Diabetes Prevalence Safety Profile Rising global aging population fueling increased incidence of age-related macular degeneration and other retinal disorders. Escalating prevalence of diabetes worldwide, leading to higher rates of diabetic eye conditions requiring treatment. Strong clinical evidence and consistent safety profile earning trust among ophthalmologists and patients alike. Product Innovation Healthcare Infrastructure Advancement in healthcare infrastructure and greater screening/diagnosis capabilities across developed and emerging markets. Major companies focusing on new product launches and delivery formats to expand treatment options and meet evolving patient needs. Projected Market Growth from 2024-2030 USD 9,714M → USD 14,545M Representing ~7% CAGR Global Eylea Market Analysis | Market Growth Drivers Apelo Consulting 4

  5. Market Segmentation by Disorder Wet Age-related Macular Degeneration (AMD) Market leader in 2024 Over 200 million affected globally, projected to reach 300 million by 2040 Diabetic Macular Edema (DME) Growing segment driven by diabetes prevalence Approximately 21 million people affected globally Myopic Choroidal Neovascularization (mCNV) Low double-digit market share in 2024 Rising prevalence in East Asia with improved diagnosis Key Insight AMD prevalence is increasing due to aging global population, driving market growth for Eylea through 2030 Other indications include Diabetic Retinopathy (DR) and Retinal Vein Occlusion (RVO) Global Eylea Market Analysis | Market Segmentation by Disorder Apelo Consulting 5

  6. Segmentation: By Product Type Prefilled Syringe Package Vial Package Largest market share in 2024 Favored for convenience and streamlined dispensing Growing preference among healthcare providers Reduces preparation time and dosing errors Popular in cost-sensitive markets Compatible with standard intravitreal administration Preferred in regions with less advanced healthcare infrastructure More economical option where cost constraints are critical Market Expansion Trends Manufacturers expanding production facilities in emerging markets Supply chain optimization reducing costs and improving efficiency Regional adaptations based on healthcare infrastructure and cost considerations Global Eylea Market Analysis | Product Type Segmentation Apelo Consulting 6

  7. Segmentation: By End User Hospitals Largest market segment due to advanced ophthalmic care infrastructure Well-established specialized experienced retinal specialists On-site pharmacy services creating ideal setting for Eylea administration eye care units with Retail Pharmacies Fast-growing segment driven by decentralized care models Increasing patient need for convenient treatment access Rise in prefilled syringes format optimized for pharmacy dispensing Others segment includes: Specialty clinics, ambulatory surgical centers, and ophthalmology practice Global Eylea Market Analysis | End User Segmentation Apelo Consulting 7

  8. Regional Market Analysis North America - Market leader in 2024, driven by robust healthcare infrastructure, policies, and high awareness of anti-VEGF therapy. supportive reimbursement Europe - ~25% market share, backed by advanced therapeutics adoption and favorable policies in Germany, France, and the UK. Asia Pacific - Fastest growth potential, driven by increasing diabetes prevalence and aging populations, especially in China, Japan, and India. Latin opportunities with expanding healthcare access. America, Middle East & Africa - Emerging Regional Growth Spotlight Asia Pacific: Highest CAGR Surging diabetes rates and improving healthcare infrastructure Global Eylea Market Analysis | Regional Market Analysis Apelo Consulting 8

  9. Key Market Highlights Wet AMD dominance: Over 200 million people affected globally, projected to reach 300 million by 2040. Diabetic Macular Edema: Affects approximately 21 million people worldwide, driving significant market growth. Prefilled syringes: Captured highest market share in 2024, expanding into emerging markets. Hospitals: Dominant end-user segment with specialized ophthalmic care infrastructure. AMD Patients 200 M+ DME Patients 21 M Growth Opportunities Increasing diagnosis rates, emerging markets expansion, and new treatment formats driving future market growth Globally (2024) Worldwide Global Eylea Market Analysis | Key Market Highlights Apelo Consulting 9

  10. Market Dynamics & Future Outlook Growth Drivers Future Outlook (2024-2030) Aging global population driving increased incidence of age- related eye disorders Rising diabetes prevalence, particularly in developing economies Enhanced healthcare infrastructure and reimbursement policies Increased disease awareness and early screening programs Challenges Strategic Forecast Continued indications Regional production scale-up in emerging markets Innovation in delivery formats and treatment regimens Greater accessibility through improved distribution networks expansion into new therapeutic Cost pressures in healthcare systems worldwide Competition from biosimilars and alternative therapies Limited access in low-resource settings Global Eylea Market Analysis | Market Dynamics & Future Outlook Apelo Consulting 10

  11. THANK YOU www.apeloconsulting.com

More Related